nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

09.05.2024 | Retinal Disorders

Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy

verfasst von: Yoko Nomura, Shuichiro Aoki, Kohdai Kitamoto, Kohei Ueda, Keiko Azuma, Tatsuya Inoue, Ryo Obata

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology

Einloggen, um Zugang zu erhalten

Abstract

Background

Long-term results of photodynamic therapy (PDT) combined with vascular endothelial growth factor (VEGF) inhibitors for pachychoroid neovasculopathy (PNV) are not yet clear.

Methods

This study is a retrospective, observational case series. We retrospectively examined untreated PNV cases (22 cases, 22 eyes, mean age of 71.0 years) who underwent PDT therapy in combination with VEGF inhibitors followed by additional treatments with pro re nata protocol. Visual acuity, number of treatments, and time to recurrence were examined. In addition, foveal choroidal thickness and choroidal vascularity index (CVI) were evaluated in 13 of 22 patients who were followed up with SpectralisOCT^R from baseline.

Results

Fifteen (68%) cases had polyps at baseline. LogMAR visual acuity averaged 0.24 ± 0.20 (range, − 0.079 to 0.82) at baseline and significantly improved after 1, 2, and 3 years (p = 0. 004, 0.0003, 0.002, respectively). Fourteen patients (64%) recurred, with an average time to recurrence of 1.8 ± 0.9 years. Foveal choroidal thickness decreased significantly after 1 year (average from 326 μm to 263 μm) and remained unchanged up to 3 years (255 μm). CVI also decreased after 1 year (average from 0.62 to 0.61) and remained unchanged until 3 years later (0.60).

Conclusions

We examined the 3-year course of PDT in combination with the VEGF inhibitor for untreated PNV. Visual acuity was improved, foveal choroidal thickness and CVI were decreased after 3 years.

Cheung CMG, Lee WK, Koizumi H et al (2019) Pachychoroid disease. Eye 33:14–33. https://doi.org/10.1038/s41433-018-0158-4CrossRefPubMed

Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659–1672. https://doi.org/10.1097/IAE.0b013e3182953df4CrossRefPubMed

Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9. https://doi.org/10.1097/IAE.0000000000000331CrossRefPubMed

Azuma K, Tan X, Asano S et al (2019) The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. PLoS One 14:e0212055. https://doi.org/10.1371/journal.pone.0212055CrossRefPubMedCentralPubMed

Matsumoto H, Hiroe T, Morimoto M et al (2018) Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62:144–150. https://doi.org/10.1007/s10384-018-0562-0CrossRefPubMed

Kinoshita T, Mori J, Hatanaka A et al (2021) Visual outcome and treatment frequency of Anti-VEGF therapy using the treat-and-extend and treatment cessation regimen for exudative age-related macular degeneration and pachychoroid neovasculopathy. Clin Ophthalmol 15:4405–4418. https://doi.org/10.2147/OPTH.S334641CrossRefPubMedCentralPubMed

Hata M, Tagawa M, Oishi A et al (2019) Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmol Retina 3:1016–1025. https://doi.org/10.1016/j.oret.2019.06.013CrossRefPubMed

Azuma K, Okubo A, Nomura Y et al (2020) Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Sci Rep 10:8337. https://doi.org/10.1038/s41598-020-65346-wCrossRefPubMedCentralPubMed

Tanaka K, Mori R, Wakatsuki Y et al (2021) Two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin Med 10:2168. https://doi.org/10.3390/jcm10102168CrossRefPubMedCentralPubMed

10.

Sacconi R, Tomasso L, Corbelli E et al (2019) Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. Eye 33:1809–1817. https://doi.org/10.1038/s41433-019-0511-2CrossRefPubMedCentralPubMed

11.

Hikichi T, Kubo N, Yamauchi M (2021) One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye 35:3367–3375. https://doi.org/10.1038/s41433-021-01418-zCrossRefPubMedCentralPubMed

12.

Yamashiro K, Yanagi Y, Koizumi H et al (2022) Relationship between pachychoroid and polypoidal choroidal vasculopathy. J Clin Med 11:4614. https://doi.org/10.3390/jcm11154614CrossRefPubMedCentralPubMed

13.

Roy R, Saurabh K, Shah D, Goel S (2019) Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor. Indian J Ophthalmol 67:1678–1683. https://doi.org/10.4103/ijo.IJO_1481_18CrossRefPubMedCentralPubMed

14.

Matsumoto H, Mukai R, Kikuchi Y et al (2020) One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64:203–209. https://doi.org/10.1007/s10384-020-00722-7CrossRefPubMed

15.

Kitajima Y, Maruyama-Inoue M, Ito A et al (2020) One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1279–1285. https://doi.org/10.1007/s00417-020-04661-4CrossRefPubMed

16.

Sartini F, Figus M, Casini G et al (2020) Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options. Int Ophthalmol 40:3577–3589. https://doi.org/10.1007/s10792-020-01522-1CrossRefPubMed

17.

Karasu B, Celebi ARC (2021) An efficacy comparison of combination of different anti-vascular endothelial growth factors and photodynamic therapy in patients with pachychoroid neovasculopathy. Int Ophthalmol 41:1989–2000. https://doi.org/10.1007/s10792-021-01754-9CrossRefPubMed

18.

Miki A, Kusuhara S, Otsuji T et al (2021) Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS One 16:e0248760. https://doi.org/10.1371/journal.pone.0248760CrossRefPubMedCentralPubMed

19.

Sato-Akushichi M, Ono S, Taneda T et al (2022) One-year outcome of combination therapy with full or reduced photodynamic therapy and one anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Pharm Basel Switz 15:483. https://doi.org/10.3390/ph15040483CrossRef

20.

Takeuchi J, Ota H, Nakano Y et al (2023) Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 261:2235–2243. https://doi.org/10.1007/s00417-023-06030-3CrossRefPubMed

21.

Hikichi T, Kubo N, Tabata M, Kurabe H (2023) Enlargement of choroidal neovascularization before recurrence after photodynamic therapy for pachychoroid neovasculopathy. Retina. https://doi.org/10.1097/IAE.0000000000003841CrossRefPubMed

22.

Tanaka N, Azuma K, Aoki S et al (2024) Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-024-06387-zCrossRefPubMed

23.

Hata M, Yamashiro K, Ooto S et al (2017) intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 58:292–298. https://doi.org/10.1167/iovs.16-20967CrossRefPubMed

24.

Park JB, Kim K, Kang MS et al (2022) Central serous chorioretinopathy: Treatment. Taiwan J Ophthalmol 12:394–408. https://doi.org/10.4103/2211-5056.362040CrossRefPubMedCentralPubMed

25.

Tagawa M, Ooto S, Yamashiro K et al (2020) Characteristics of pachychoroid neovasculopathy. Sci Rep 10:16248. https://doi.org/10.1038/s41598-020-73303-wCrossRefPubMedCentralPubMed

26.

Elfandi S, Ooto S, Miyata M et al (2021) Effects of intravitreous aflibercept injection in pachychoroid neovasculopathy: Comparison with typical neovascular age-related macular degeneration. Clin Ophthalmol 15:1539–1549. https://doi.org/10.2147/OPTH.S285257CrossRefPubMedCentralPubMed

27.

Tanaka K, Oguchi Y, Omori T et al (2021) Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease. Sci Rep 11:8464. https://doi.org/10.1038/s41598-021-87340-6CrossRefPubMedCentralPubMed

28.

Spaide RF (2018) Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. Retina 38:708–716. https://doi.org/10.1097/IAE.0000000000001689CrossRefPubMed

29.

Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829–1837. https://doi.org/10.1097/IAE.0b013e3182680a66CrossRefPubMed

30.

Dansingani KK, Balaratnasingam C, Klufas MA et al (2015) Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 160:1243-1254.e2. https://doi.org/10.1016/j.ajo.2015.08.028CrossRefPubMed

31.

Miyake M, Ooto S, Yamashiro K et al (2015) Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5:16204. https://doi.org/10.1038/srep16204CrossRefPubMedCentralPubMed

32.

Bressler NM (1960) Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol Chic Ill 119:198–207

33.

Nomura Y, Takahashi H, Tan X et al (2014) Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration. Jpn J Ophthalmol 58:443–447. https://doi.org/10.1007/s10384-014-0333-5CrossRefPubMed

34.

Betzler BK, Ding J, Wei X et al (2022) Choroidal vascularity index: a step towards software as a medical device. Br J Ophthalmol 106:149–155. https://doi.org/10.1136/bjophthalmol-2021-318782CrossRefPubMed

35.

Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019CrossRefPubMed

36.

Agrawal R, Chhablani J, Tan K-A et al (2016) Choroidal vascularity index in central serous chorioretinopathy. Retina 36:1646–1651. https://doi.org/10.1097/IAE.0000000000001040CrossRefPubMed

37.

Kuroda Y, Yamashiro K, Tsujikawa A et al (2016) Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment. Am J Ophthalmol 161:94-103.e1. https://doi.org/10.1016/j.ajo.2015.09.032CrossRefPubMed

38.

Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367–374. https://doi.org/10.1016/s0039-6257(05)80092-xCrossRefPubMed

39.

Takahashi K, Shiraga F, Ishida S et al (2015) Diagnostic criteria for atrophic age-related macular degeneration. Nippon Ganka Gakkai Zasshi 119:671–677PubMed

40.

Sadda SR, Guymer R, Monés JM et al (2020) Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: Systematic literature review and expert opinion. Ophthalmology 127:648–659. https://doi.org/10.1016/j.ophtha.2019.11.010CrossRefPubMed

41.

Jung BJ, Kim JY, Lee JH et al (2019) Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep 9:2055. https://doi.org/10.1038/s41598-019-38504-yCrossRefPubMedCentralPubMed

42.

Cho HJ, Jung SH, Cho S et al (2019) Intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 35:174–181. https://doi.org/10.1089/jop.2018.0107CrossRef

43.

Tong Y, Zhao K-K, Feng D et al (2016) Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review. Int J Ophthalmol 9:1028–1037. https://doi.org/10.18240/ijo.2016.07.16CrossRefPubMedCentralPubMed

44.

Maruko I, Iida T, Sugano Y et al (2011) One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 31:1921–1927. https://doi.org/10.1097/IAE.0b013e31822bf6b1CrossRefPubMed

45.

Park W, Kim M, Kim RY, Park Y-H (2019) Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol 257:2155–2161. https://doi.org/10.1007/s00417-019-04426-8CrossRefPubMed

46.

Lee JH, Lee WK (2016) One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. Retina 36:889–895. https://doi.org/10.1097/IAE.0000000000000809CrossRefPubMed

47.

Chan W-M, Lam DSC, Lai TYY et al (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458. https://doi.org/10.1136/bjo.87.12.1453CrossRefPubMedCentralPubMed

48.

Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U et al (1960) (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol Chic Ill 120:835–844

49.

Lim TH, Lai TYY, Takahashi K et al (2020) Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmol 138:935–942. https://doi.org/10.1001/jamaophthalmol.2020.2443CrossRefPubMedCentralPubMed

50.

Kikushima W, Sakurada Y, Sugiyama A et al (2017) Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab. Jpn J Ophthalmol 61:61–66. https://doi.org/10.1007/s10384-016-0479-4CrossRefPubMed

51.

Miyakubo T, Mukai R, Matsumoto H et al (2023) Comparison of the 2-year results of photodynamic therapy with aflibercept and aflibercept monotherapy for polypoidal choroidal vasculopathy. Clin Ophthalmol 17:571–577. https://doi.org/10.2147/OPTH.S386222CrossRefPubMedCentralPubMed

52.

van Rijssen TJ, van Dijk EHC, Scholz P et al (2021) Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. Graefes Arch Clin Exp Ophthalmol 259:905–910. https://doi.org/10.1007/s00417-020-04959-3CrossRefPubMed

53.

Kawai K, Miyata M, Ooto S et al (2023) Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy. Eye 37:1067–1072. https://doi.org/10.1038/s41433-022-02067-6CrossRefPubMed

54.

Castro-Navarro V, Behar-Cohen F, Chang W et al (2021) Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol 259:1385–1400. https://doi.org/10.1007/s00417-020-04940-0CrossRefPubMed

Titel: Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy
verfasst von: Yoko Nomura
Shuichiro Aoki
Kohdai Kitamoto
Kohei Ueda
Keiko Azuma
Tatsuya Inoue
Ryo Obata
Publikationsdatum: 09.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-024-06499-6

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

CME: Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

CME: Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde